@citizenptnewsms.bsky.socialBig news for students! The board just approved new dual-credit agreements with Southeastern Baptist College and Mississippi Gulf Coast Community College, paving the way for expanded access to collegiate and career-technical education in 2026–27.
Click to read more!
@citizenptnewsms.bsky.socialThe Jackson County School District's Board of Trustees just made a game-changing decision, approving a sweeping consent agenda that could reshape the educational landscape for years to come!
Click to read more!
#MS #CitizenPortal #CommunityInvolvement #SustainableEnergy #MississippiSchools
@klassmi.bsky.social#MS NOW WH reporter Laura Barrón-López was denied access this morning, despite a ruling on Wednesday by U.S. District Judge Kelly. Kelly issued a 14-day temporary restraining order restoring access to MS NOW, CNN and Politico after Trump banned the outlets. #Outlaws ⚖️
www.youtube.com/watch?v=VOzc...
@klassmi.bsky.social#MS NOW WH reporter Laura Barrón-López was denied access this morning, despite a ruling on Wednesday by U.S. District Judge Kelly. Kelly issued a 14-day temporary restraining order restoring access to MS NOW, CNN and Politico after Trump banned the outlets. #Outlaws ⚖️
www.youtube.com/watch?v=VOzc...
@nieuwsjunkies.nl🕔 17:01 | RTL Nieuws
🔸 #MS #WitteHuis #USA #Journalisten #Rechtbank
@nieuwsjunkies.nl🕞 15:22 | RTL Nieuws
🔸 #Trump #MS #WitteHuis #Journalisten #Rechter
@rod2ik.bsky.social
@stuartlabrum.bsky.socialFederal judge orders White House to restore access for CNN. MS NOW, Politico #WhiteHousePressPool #CNN #MS-NOW #Politico #PressFreedom #FreePressBan #UnitedStates
@fr-ch.pds.netasgard.comDonald Trump — Un juge fédéral ordonne à la Maison Blanche de rétablir l'accès à CNN, MS NOW et Politico après une décision de Donald Trump. #MS #CNN #Politico #DonaldTrump #News
@virussucks.com![Vol. 18, No. 868
No access
Research Article
MULTIPLE SCLEROSIS
Share on
The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis
Praveen Yerramothu https://orcid.org/0000-0001-6635-6681, Kameshwari Ambati, [...] , and Jayakrishna Ambati https://orcid.org/0000-0003-1622-6365+36 authors Authors Info & Affiliations
Science Translational Medicine
23 Sep 2026
Vol 18, Issue 868
DOI: 10.1126/scitranslmed.aei2870
Information & Authors
Metrics & Citations
Check Access
References
Share
Abstract
Innate immune signaling through inflammasome activation has been implicated in the pathogenesis of multiple sclerosis (MS). We previously demonstrated that nucleoside reverse transcriptase inhibitors (NRTIs), drugs approved to treat HIV and hepatitis B virus infections, and kamuvudines, safer NRTI derivatives, both inhibit inflammasome activation. Here, we report that in the experimental autoimmune encephalitis mouse model of MS, treatment with kamuvudine-9 (K-9), an NRTI derivative with an enhanced safety profile, prevented further neurological deficits and reversed preexisting paralysis and vision loss. K-9 promoted myelin and axonal preservation in the mouse spinal cord and abolished the increase in serum neurofilament light (NfL) chain. K-9 disrupted interactions between nucleotide-binding domain leucine-rich repeat (NLR) pyrin domain-containing protein 3 (NLRP3) and NIMA-related kinase 7 (NEK7) and between NLRP3 and NLR CARD domain containing 4 (NLRC4), inhibiting dual inflammasome activation. K-9 also exhibited appropriate safety and pharmacokinetic characteristics and biodistribution. In three distinct human cohorts, there was a lower incidence of MS in those individuals receiving NRTIs for HIV infection, preexposure prophylaxis for HIV, or hepatitis B virus infection. NRTI use was also associated with a reduction in relapse rate in individuals with MS. These findings provide a rationale for further investigating](https://cdn.bsky.app/img/feed_fullsize/plain/did:plc:szc7xq5qv7wg2abye6tlvet2/bafkreiaczc6wdt6jwetsga6huzyvjos2koadwthlnvs7673t7gsfc225fe@jpeg)
@ta-in.pds.netasgard.com
@onpolitics.news
@sl-si.pds.netasgard.com
@sv-se.pds.netasgard.com
@ru-ru.pds.netasgard.com
@pt-pt.pds.netasgard.com
@bg-bg.pds.netasgard.com
@fr-be.pds.netasgard.com